Ms. Sarah Boyce's most recent trade in Atrium Therapeutics Inc. was a trade of 126,418 Common Stock done at an average price of $8.9 . Disclosure was reported to the exchange on Sept. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atrium Therapeutics Inc | Ms. Sarah Boyce | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.95 per share. | 18 Sep 2026 | 126,418 | 138,668 | - | 8.9 | 1,131,441 | Common Stock |
| Contineum Therapeutics Inc (Class A) | Ms. Sarah Boyce | Director | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | ||
| Atrium Therapeutics Inc | Ms. Sarah Boyce | Director | 27 Feb 2026 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | ||
| Contineum Therapeutics Inc (Class A) | Ms. Sarah Boyce | Director | 26 Jun 2025 | 14,750 | 14,750 | - | - | Stock Option (right to buy) | ||
| Contineum Therapeutics Inc (Class A) | Ms. Sarah Boyce | Director | 24 Jun 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | 18 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | 18 Jun 2024 | 20,000 | 0 | - | - | Restricted Stock Units | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | 18 Jun 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 68,381 | - | - | Common Stock | |
| OmniAb Inc | Ms. Sarah Boyce | Director | 23 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | 23 Jun 2023 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| OmniAb Inc | Ms. Sarah Boyce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 39,628 | 48,381 | - | - | Common Stock | |
| Ligand Pharma Inc (Class B) | Ms. Sarah Boyce | Former Director | 01 Nov 2022 | 4,340 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Ms. Sarah Boyce | Former Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 1,004 | 2,892 (0%) | 0% | - | Common Stock | |
| Ligand Pharma Inc (Class B) | Ms. Sarah Boyce | Director | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Ms. Sarah Boyce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 3,896 (0%) | 0% | 0 | Common Stock |